Managed Care

 

Step therapy for antidepressants saves 11.7 percent in one year

MANAGED CARE November 2006. © MediMedia USA
The Formulary Files

Step therapy for antidepressants saves 11.7 percent in one year

MANAGED CARE November 2006. ©MediMedia USA













Results of the implementation of a step therapy edit that required HMO members to use a generic antidepressant, excluding tricyclic antidepressants, before using a brand-name antidepressant resulted in drug cost savings of 11.7 percent for the entire class of antidepressants. That worked out to 36 cents per member per month.

The step therapy edit applied only to members with no claim history of antidepressant treatment for the preceding six months. These members were required to use a generic antidepressant. The $5–$10 copayment was waived for the first prescription. Preferred brand-name antidepressants were in tier 2, with a copayment of $20–$25 or coinsurance of 25 percent. Nonformulary brand antidepressants were in tier 3 of the formulary, with a copayment of $40–$45 or coinsurance of 50 percent. Findings were published in the Journal of Managed Care Pharmacy.

The researchers found that the dispensing rate for generic antidepressants increased by 20 percentage points (32.5 percent to 52.5 percent) in the intervention group, but only 7.4 percentage points (24.9 percent to 32.3 percent) in the comparison group (beneficiaries who were not subject to interventions involving antidepressant drug therapy in either 2004 or 2005). Antidepressant drug cost per day of therapy in the intervention group decreased by 11.7 percent in 2005, compared with the previous year. The control group saw a 2.7 percentage point decrease.

"Many MCOs have followed our lead in implementing generic step edits," says Jeffrey D. Dunn, PharmD, MBA, formulary and contract manager at SelectHealth Plans (formerly IHC Health Plans) and lead author. He says the study only focuses on pharmacy costs, and further research is necessary to report about the associated medical costs.

Primary outcomes for the intervention group versus comparison group for antidepressants

Source: J Manag Care Pharm 2006;12(4):294–302

Meetings

Pharmaceutical Pricing and Contracting Conference Philadelphia, PA September 22–23, 2014
Private Health Insurance Exchanges Conference Washington, D.C. October 7–8, 2014
National Healthcare Facility Management Summit Palm Beach, FL October 16–17, 2014
National Healthcare CFO Summit Las Vegas, NV October 19–21, 2014
National Healthcare CXO Summit Las Vegas, NV October 19–21, 2014
Innovative Member Engagement Operations For Health Plans Las Vegas, NV October 20–21, 2014
4th Partnering With ACOs Summit Los Angeles, CA October 27–28, 2014
2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014